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188 Abstractsthe mechanisms and consequences of bone fragility in vitro in specimens and
in vivo in laboratory animals.
Now, for this 20th IBDW, we have assembled senior scientists and clinicians,
along with post-doctoral students and trainees, to observe and deliver an
amazing array of presentations covering traditional and more novel de-
velopments and applications of CT, MRI and ultrasound imaging and
quantification. We address not only morphological imaging but also func-
tional, cellular and molecular imaging. We explore not only technical
developments related to imaging the osseous tissues but also to imaging
and quantifying muscular, cartilaginous, vascular and hematopoietic tissues
across a range of disorders.
In summary, the past four decades have witnessed tremendous progress in
the development and application of quantitative bone and soft tissue
imaging techniques. These currently provide a vast array of exquisite
research and clinical tools to examine and explore the depths and
boundaries of human and animal tissues in health and disease. Over this
time interval, The International Bone Density Workshop series, and its
leaders, participants and sponsors have been instrumental, indeed pivotal,
in promoting and fostering the development, advancement and maturation
of these most exciting research arenas.Table. International bone density workshops e presidents, locations and
years.
Presidents Conference Locations Year
1 Harry K. Genant San Francisco, California,
USA
1979
2 Peter Ruegsegger Zuoz, Switzerland 1981
3 Thomas R. Overton &
Thomas N. Hangartner
Banff, Canada 1982
4 Anne-Marie Laval-Jeantet Fontevraud, France 1984
5 Frederick S. Kaplan Bretton Woods,
New Hampshire, USA
1985
6 Judith E. Adams Buxton, England 1987
7 Bruce Ettinger Rancho Mirage,
California, USA
1989
8 Dieter Felsenberg &
Willi Kalender
Bad Reichenhall, Germany 1991
9 Dianna D. Cody &
Bradford J. Richmond
Traverse City, Michigan, USA 1992
10 Sergio Ortolani &
Maria Luisa Bianchi
Venice, Italy 1994
11 Kenneth G. Faulkner &
Michael R. McClung
Gleneden Beach, Oregon, USA 1995
12 David Reid & Peter Tothill Crieff, Scotland 1997
13 Charles R. Wilson Delavan, USA 1998
14 Claus Glueer Warnemuende, Germany 2000
15 Sharmila Majumdar &
John Shepherd
Monterey, California, USA 2002
16 Didier Hans & Pascal Laugier Annecy, France 2004
17 Akira Itabashi, Masako Ito &
Masao Fukunaga
Kyoto, Japan 2006
18 Giuseppe Guglielmi Pugnochiuso, Italy 2008
19 Paul D. Miller Breckenridge, Colorado, USA 2012
20 Ling Qin & James F. Griffith Hong Kong 2014Brief CV
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Second only to cardiovascular disease in producing long term disability[1],
osteoarthritis (OA) is a chronic degenerative disease in which the salient
feature is the progressive loss of articular cartilage. Traditionally, OA has
been diagnosed via radiographic examination, which relies on the assess-
ment of secondary indicators of disease such as the presence or absence of
osteophytes and the width of the joint space for diagnosis [2,3]. However,
this approach is limited in that it is effective only at later stages of disease
progression because soft tissue quality can only be inferred from relative
bone appearance and health using planar X-ray imaging techniques [4].
Moreover, in OA the early stages of cartilage degeneration are often marked
by the loss of specific biologic components of the cartilage matrix [5e8]:
changes that are invisible in conventional radiographs.
Magnetic resonance imaging (MRI) has been used to assess cartilage
morphology directly and has shown promise for the detection of soft tissue
changes 4, 9e12. In particular, T2 and T1r relaxation times have proven to
be valuable in the assessment of cartilage biochemistry, in particular
hydration, proteoglycan and collagen content, and collagen orientation
[9e15]. T2 tissue relaxation time has been found to be inversely correlated
with both cartilage volume and thickness, and focal areas of increased T2
Abstracts 189levels have been found to correspond to cartilage lesions upon arthroscopic
evaluation [14e17]. Lesions found in T2-weighted images and T2 maps have
also been correlated with degradations of cartilage matrix (i.e., fibrillation,
clefts [14,15]). T1r describes longitudinal relaxation in the rotating frame,
and has been associated with proteoglycan loss, which is thought to precede
the development of symptomatic.
Assessment of bone quality in OA using MR and micro-computed tomography
(mCT) in bone samples has also revealed much information about bone
density and micro-architecture.
Although the disruptive and degradative events accompanying the advent of
disease progression in OA are known, the mechanisms and order in which
these events occur is still an active area of research. Preclinical studies
designed to address this need employ several animal models, which exhibit
disease phenotypes similar to those observed in humans. These studies will
be reviewed in this talk, and future directions will be identified.
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The XtremeCT (Scanco Medical AG, Bruttisellen, Switzerland) developed in
2004 was the first scanner to propose in vivo assessment of
trabecular microarchitecture at the ultradistal radius and tibia. At that
time we proposed a 2.8 min scan over a 9.02 mm region, with 82 mm voxel
size, for a radiation dose lower than 3 mSv [Laib et al e Bone 1999].
This was the chance to pursue at the in vivo and organic level all the bone
research done at the tissue level with restricted region of interest as per his-
tomorphometry. Various studies exploited this new opportunity to better un-
derstand the mechanisms of bone loss in osteoporosis or the actions of drugs
affecting bone metabolism.
During the past decade, applications focused on bone research are being
developed as cortical bone analysis, finite element analyses or
3D registration. But bone is not the only field that can take advantage
of the XtremeCT. Research in rheumatoid arthritis also finds interest
into bone erosions, or joint space width in 3D that can be obtained from
high resolution joint imaging [SPECTRA]. With the interest in sarcopenia
growing in the community, we are currently validating a method to
assess muscle volume to fully exploit the images obtained with XtremeCT,
even on the low density range [Erlandson et al e ASBMR 2012].
Vascular calcification may also be assessed, in addition to bone micro-
architecture changes in patients suffering chronic kidney disease, or
diabetes [Patsch].
Movement artifacts are known to affect XtremeCT scans, notably at the
radius. They impact the reproducibility of the measurements and reduce the
number of valid scans in longitudinal studies on bone fragility or osteoporosis
treatment efficacy [Pialat et al e Bone 2011].
This motivated the design of a new HR-pQCT scanner (XtremeCT II) to address
the movement artifacts issue. Hardware improvements allow for scan time
shortening with no cost on image quality, with two different scan protocols
over a 10 mm range. The basic protocol was specified to be compatible with
XtremeCT: 1.5 min scan, 82 mm voxel size and 3 mSv dose. The second protocol
has better resolution and is still acceptable for patient scans: 61 mmvoxel size,
2 min scan time and 5 mSv dose.
A set of 20 cadaver bone phantoms (EBS, UCSF) was scanned to compare
results across the different scan protocols, between XtremeCT II, XtremeCT
and mCT 100. We obtained excellent correlations between all datasets, andgood agreements were met between XtremeCT II both at 82 and 61 mm when
compared to XtremeCT. We also found that the accuracy of bone micro-
architecture measurements improved as the voxel size decreased, with
respect to mCT 100 results.
Reduced scan time should lead to significant improvements regarding
movement artifacts on in vivo scans. Also a new forearm cast will help to
limit patient mobility.
XtremeCT II is also able to scan at 30 mm voxel size, which may find use in ex
vivo studies or preclinical research involving relatively large animals such as
rabbits.
XtremeCT II does not only improve the research in osteoporosis, but is more
flexible hence widening the horizon of its applications.Brief CV
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